lclat1 Antibody

What is LCLAT1 and why is it important for cellular signaling research?

LCLAT1 (Lysocardiolipin acyltransferase 1) is a multifunctional enzyme critical for phospholipid metabolism and cellular signaling. It exhibits acyl-CoA:lysocardiolipin acyltransferase (ALCAT) activity and catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling. LCLAT1 is essential for receptor tyrosine kinase signaling, particularly in EGF-mediated pathways. Recent research has demonstrated that LCLAT1 silencing abates PtdIns(3,4,5)P3 levels in response to EGF signaling and impairs Akt activation and downstream signaling . Furthermore, LCLAT1 plays crucial roles in hematopoiesis, cell differentiation, and mitochondrial function, making it an important target for antibody-based research in multiple biological contexts .

What applications are LCLAT1 antibodies suitable for in molecular biology research?

LCLAT1 antibodies have been validated for multiple research applications with varying optimization requirements:

When selecting application parameters, researchers should consider that LCLAT1 is primarily localized to the cytoplasm, specifically to the endoplasmic reticulum, which affects experimental design and interpretation .

How should researchers design siRNA experiments to study LCLAT1 function?

When designing siRNA experiments to study LCLAT1 function, follow this methodological approach:

• siRNA Selection: Use validated oligonucleotides targeting different regions of LCLAT1. Research indicates successful silencing with specific sequences like 5′-GGAAAUGGAAGGAUGACAAUU-3′ (siLCLAT1-1) and commercially available validated siRNAs like siGenome D-010307-01-0002 (siLCLAT1-5) .

• Transfection Protocol:

  • Use 22 pmol siRNA/well with Lipofectamine RNAiMAX in Opti-MEM reduced serum media

  • Incubate for 3 hours at 37°C with 5% CO2

  • Perform two rounds of transfection (72 and 48 hours before experiments)

  • Include non-targeting control siRNA (e.g., 5′-CGUACUGCUUGCGAUACGGUU-3′)

• Validation of Knockdown:

  • Assess silencing efficiency via Western blotting

  • Target reduction should be at least 70% compared to control

  • Examine multiple LCLAT1 siRNAs to control for off-target effects

• Experimental Readouts: Recent studies demonstrate that LCLAT1 silencing affects:

  • PtdIns(3,4,5)P3 levels after EGF stimulation

  • Phosphorylation of Akt (S473) and downstream targets

  • Phosphorylation of TSC2 (T1462) and GSK3β (S9)

What controls are essential when studying LCLAT1's role in EGF signaling?

When investigating LCLAT1's function in EGF signaling pathways, implement these critical controls:

• Pathway Activation Controls:

  • Positive control: EGF stimulation (100 ng/ml) in non-silenced cells should increase phosphorylation of EGFR (Y1068), Akt (S473), TSC2 (T1462), and GSK3β (S9)

  • Negative control: Serum-starved cells without EGF stimulation

  • Time course controls: Examine phosphorylation at multiple time points (5-30 min) to capture transient signaling events

• Specificity Controls:

  • Multiple siRNA sequences targeting LCLAT1 to differentiate true phenotypes from off-target effects

  • Rescue experiments expressing siRNA-resistant LCLAT1 constructs

  • Examination of EGFR surface levels and phosphorylation to confirm specific effects on downstream signaling

• Loading Controls:

  • Total protein controls (vinculin, GAPDH, cofilin) to normalize phosphorylation signals

  • Total kinase levels (total Akt, total ERK) to differentiate changes in phosphorylation from changes in protein abundance

• Cell Type Controls:

  • Use multiple cell lines (e.g., both MDA-MB-231 and ARPE-19) to confirm findings across cellular contexts

How can LCLAT1 antibodies help elucidate the mechanism of PtdIns acyl remodeling in receptor tyrosine kinase signaling?

LCLAT1 antibodies are instrumental in elucidating PtdIns acyl remodeling in receptor tyrosine kinase signaling through several methodological approaches:

• Protein-Lipid Interaction Studies:

  • LCLAT1 antibodies can immunoprecipitate the enzyme to analyze its association with specific phospholipid species

  • Combined with lipidomic analysis, this approach reveals LCLAT1's role in enriching PtdIns in stearate at the sn-1 position, which is critical for maintaining pools of 38:4-PtdIns(3,4,5)P3 required for Akt activation

• Subcellular Localization Analysis:

  • Immunofluorescence with LCLAT1 antibodies demonstrates its ER localization, providing insight into how it contributes to the PtdIns cycle

  • Co-localization studies with phospholipid biosynthesis markers can track PtdIns synthesis and transport to the plasma membrane

• Temporal Dynamics of Signaling:

  • LCLAT1 antibodies enable time-course studies of protein expression during EGF stimulation

  • Research shows that LCLAT1 activity is required for maintaining PtdIns(3,4,5)P3 levels specifically during receptor tyrosine kinase activation

• Lipidomic Integration:

  • Combining LCLAT1 immunoblotting with mass spectrometry of phospholipids reveals that LCLAT1 silencing alters the ratio of 38:4-PtdIns(3,4,5)P3 to 36:x-PtdInsP after EGF stimulation

  • This methodological approach demonstrates LCLAT1's role in maintaining specific acyl profiles critical for signaling

What methodological approaches can detect changes in LCLAT1 function during mitochondrial stress?

To investigate LCLAT1 function during mitochondrial stress, researchers should employ these sophisticated methodological approaches:

• Dual-Function Analysis Protocol:

  • LCLAT1 exhibits both cardiolipin remodeling and PtdIns acylation activities

  • Use subcellular fractionation followed by immunoblotting with LCLAT1 antibodies to track redistribution between ER and mitochondria-associated membranes during stress

• Enzymatic Activity Assays:

  • Immunoprecipitate LCLAT1 using validated antibodies

  • Measure acyltransferase activity with different substrates (lysocardiolipin, lyso-PtdIns) to determine if stress alters substrate preference

  • Compare activity with different acyl-CoA donors (linoleoyl-CoA, oleoyl-CoA) to assess changes in acyl chain specificity

• Mitochondrial Dynamics Integration:

  • LCLAT1 interconnects with Tafazzin (TAZ), another enzyme critical in cardiolipin biosynthesis and remodeling

  • Combined immunofluorescence for both proteins during stress reveals coordination of these pathways

• Phospholipid Profiling:

  • Correlate LCLAT1 expression levels with changes in cardiolipin species and PtdIns/PtdInsP acyl profiles during oxidative stress

  • Data indicates that LCLAT1 regulation may shift between its dual functions depending on cellular stress conditions

How can researchers troubleshoot inconsistent LCLAT1 antibody performance in Western blotting?

When encountering inconsistent LCLAT1 antibody performance in Western blotting, follow this systematic troubleshooting approach:

• Antibody Selection Considerations:

  • Epitope location: Different commercial antibodies target distinct regions of LCLAT1 (e.g., aa 200-350, aa 150-C-terminus, aa 261-360/414)

  • Known detection pattern: LCLAT1 typically appears as a major band at approximately 35 kDa in Western blots from ARPE-19 and MDA-MB-231 cells

  • Cross-reactivity profile: Check predicted reactivity with human, mouse, rat, and other species based on sequence homology

• Sample Preparation Optimization:

  • Cell lysis buffer composition: Include phosphatase inhibitors when studying signaling pathways

  • Protein loading: 20-40 μg total protein per lane typically provides optimal signal

  • Denaturation conditions: Test both reducing and non-reducing conditions if inconsistent results occur

• Protocol Modifications for Signal Enhancement:

  • Blocking optimization: Test both BSA and milk-based blocking solutions

  • Primary antibody dilution: Titrate between 1:300-1:5000 depending on the specific antibody

  • Secondary antibody selection: HRP-linked anti-rabbit IgG antibodies are typically most effective

  • Extended incubation: Consider overnight incubation at 4°C for primary antibody

• Technical Validation Approaches:

  • Multiple antibody comparison: Test antibodies from different vendors targeting distinct epitopes

  • siRNA controls: Include LCLAT1-silenced samples to confirm band specificity

  • Positive controls: Include cell types known to express LCLAT1 at high levels

What methodological strategies optimize LCLAT1 detection in immunofluorescence studies?

To optimize LCLAT1 detection in immunofluorescence studies, implement these research-validated methodological strategies:

• Fixation Method Selection:

  • Paraformaldehyde (4%) fixation for 15 minutes preserves subcellular structures while maintaining antigenicity

  • For mitochondrial co-localization studies, brief glutaraldehyde (0.1%) addition can improve ultrastructural preservation

  • Cold methanol fixation may enhance detection of certain epitopes

• Antibody Concentration Optimization:

  Application Type	Starting Dilution	Optimization Range
  IF(IHC-P)	1:100	1:50-1:200
  IF(IHC-F)	1:100	1:50-1:200
  IF(ICC)	1:100	1:50-1:200
  Immunofluorescence (general)	-	0.25-2 μg/mL

• Antigen Retrieval Methods:

  • Heat-mediated retrieval in citrate buffer (pH 6.0) for paraffin sections

  • For frozen sections, test with and without retrieval to determine optimal conditions

  • Extended permeabilization (0.2% Triton X-100, 15-20 minutes) may improve nuclear detection

• Signal Amplification Strategies:

  • Tyramide signal amplification for low-abundance detection

  • Secondary antibody selection: fluorophore-conjugated anti-rabbit antibodies with minimal cross-reactivity

  • Counter-staining optimization: DAPI for nuclei, phalloidin for actin cytoskeleton, and organelle-specific markers for co-localization studies

How should researchers interpret changes in LCLAT1 expression in relation to PI3K/Akt signaling dynamics?

When interpreting changes in LCLAT1 expression and its impact on PI3K/Akt signaling, consider these analytical frameworks:

• Temporal Signaling Correlation Analysis:

  • LCLAT1 silencing impairs EGF-driven and insulin-driven Akt activation

  • The effect is most pronounced on sustained Akt signaling rather than initial activation

  • LCLAT1 expression correlates with phosphorylation of Akt downstream targets including TSC2 and GSK3β

• Pathway-Specific Effects Interpretation:

  • LCLAT1 disruption affects PI3K signaling more than MAPK/ERK pathway activation

  • LCLAT1 silencing doesn't impair EGFR phosphorylation at Y1068, indicating its effects are downstream of receptor activation

  • Data suggests LCLAT1 specifically affects PtdIns(3,4,5)P3-dependent signaling rather than all EGFR-mediated pathways

• Quantitative Analysis Framework:

  Signaling Parameter	Effect of LCLAT1 Silencing	Statistical Significance
  EGFR phosphorylation (Y1068)	No reduction (may increase)	p > 0.05
  Akt phosphorylation (S473)	Significant reduction	p < 0.05
  TSC2 phosphorylation (T1462)	Significant reduction	p < 0.05
  GSK3β phosphorylation (S9)	Significant reduction	p < 0.05
  PtdIns(3,4,5)P3 levels after EGF	Significant reduction	p < 0.05

• Cell-Type Dependent Variation:

  • LCLAT1 silencing affects PtdIns acyl profiles differently between cell types:

    • In ARPE-19 cells: Altered 38:4 bis-PtdInsPs profile

    • In MDA-MB-231 cells: Changed 38:4 mono-PtdInsPs profile

  • These differences suggest cell-type specific lipid metabolism pathways affect how LCLAT1 influences signaling

What analytical framework should be used to distinguish direct versus indirect effects of LCLAT1 on receptor tyrosine kinase signaling?

To distinguish direct versus indirect effects of LCLAT1 on receptor tyrosine kinase signaling, implement this comprehensive analytical framework:

• Temporal Resolution Analysis:

  • Early signaling events (0-5 minutes): LCLAT1 silencing doesn't significantly affect EGFR phosphorylation, suggesting no direct role in receptor activation

  • Intermediate events (5-15 minutes): Reduced PtdIns(3,4,5)P3 generation indicates direct effects on PI3K pathway

  • Late events (15-60 minutes): Impaired Akt substrate phosphorylation may reflect both direct and indirect effects

• Substrate-Specific Phospholipid Profiling:

  • Direct effects: LCLAT1 silencing alters the acyl profile of specific PtdInsP species

  • Changes in 38:4-PtdIns(3,4,5)P3 relative to 36:x-PtdInsP after EGF stimulation directly link LCLAT1 to receptor-activated PI3K signaling

  • Quantify changes in:

    • PtdIns acyl profiles

    • Mono-phosphorylated PtdInsPs

    • Bis-phosphorylated PtdInsPs

    • Tris-phosphorylated PtdInsPs

• Rescue Experiment Paradigm:

  • Test rescue with:

    • Wild-type LCLAT1

    • Catalytically dead LCLAT1 mutants

    • LCLAT1 with altered substrate specificity

  • Direct effects should be rescued by catalytically active enzyme but not inactive mutants

• Protein Interaction Network Analysis:

  • Test direct interaction with:

    • PI3K complex components

    • PtdIns kinases/phosphatases

    • EGFR complex proteins

  • Indirect effects likely manifest through altered lipid composition rather than protein-protein interactions

What specialized techniques should researchers master to effectively study LCLAT1's dual role in cardiolipin remodeling and phosphoinositide metabolism?

To comprehensively investigate LCLAT1's dual functionality, researchers should master these specialized techniques:

• Lipidomic Profiling with Mass Spectrometry:

  • LC-MS/MS methodology optimized for phospholipid detection

  • Targeted analysis of acyl chain compositions in:

    • PtdIns species (particularly 38:4-PtdIns vs. 36:x-PtdIns)

    • PtdInsP species at all phosphorylation states

    • Cardiolipin and lyso-cardiolipin species

  • Internal standards selection for accurate quantification

• Subcellular Fractionation for Compartment-Specific Analysis:

  • Density gradient ultracentrifugation to separate:

    • Endoplasmic reticulum (primary LCLAT1 location)

    • Mitochondria-associated membranes

    • Plasma membrane fractions

    • Mitochondrial fractions

  • Western blotting with compartment-specific markers to validate fractionation purity

• Live-Cell Phosphoinositide Imaging:

  • Expression of fluorescent PtdInsP reporters (e.g., PH domains)

  • FRET-based sensors for real-time PtdInsP dynamics

  • Integration with LCLAT1 knockdown or overexpression systems

  • Quantitative analysis of PtdInsP reporter localization and intensity

• In Vitro Enzymatic Activity Assays:

  • Purification of recombinant LCLAT1 or immunoprecipitation from cells

  • Radiometric assays using [14C]-labeled acyl-CoA donors

  • Comparison of activity toward multiple substrates:

    • Lyso-cardiolipin

    • Lyso-PtdIns

    • Lyso-phosphatidic acid

  • Testing substrate preferences under varying conditions

How should researchers design experiments to investigate the LCLAT1-mediated link between mitochondrial function and receptor tyrosine kinase signaling?

To investigate the LCLAT1-mediated connection between mitochondrial function and receptor tyrosine kinase signaling, implement this sophisticated experimental design framework:

• Coordinated Analysis of Dual Pathways:

  • Simultaneous monitoring of:

    • Mitochondrial membrane potential (TMRM, JC-1 dyes)

    • Phosphoinositide dynamics (PH domain reporters)

    • LCLAT1 localization (fluorescent tagging or immunofluorescence)

    • Akt activation (phospho-specific antibodies)

  • Time-course correlation after EGF stimulation

• Genetic Manipulation Strategy:

  • CRISPR/Cas9 editing of LCLAT1 to create:

    • Complete knockout cell lines

    • Point mutations affecting specific activities

    • Domain-specific modifications

  • Rescue experiments with:

    • Wild-type LCLAT1

    • Mitochondria-targeted LCLAT1

    • ER-restricted LCLAT1

• Organelle Interaction Analysis:

  • Proximity labeling (BioID, APEX) to identify LCLAT1 interactors at:

    • Mitochondria-ER contact sites

    • Plasma membrane-ER junctions

  • Live-cell imaging of organelle contacts during signaling

  • Electron microscopy to visualize ultrastructural changes

• Metabolic-Signaling Integration:

  • Measure changes in:

    • ATP production (Seahorse analyzer)

    • Reactive oxygen species (H2DCF-DA, MitoSOX)

    • Calcium dynamics (Fluo-4, Rhod-2)

  • Correlate with:

    • PtdIns(3,4,5)P3 levels

    • Akt pathway activation

    • Downstream metabolic enzyme phosphorylation

This experimental approach would reveal how LCLAT1's dual roles in cardiolipin remodeling and phosphoinositide metabolism coordinate mitochondrial function with receptor tyrosine kinase signaling cascades.